Wilkinson: What is the Deal with Esketamine?
Samuel Wilkinson, MD, Assistant Professor of Psychiatry and Assistant Director of the Yale Depression Research Program, writes in Psychiatric Times about the drug esketamine, approved by the U.S. Food and Drug Administration last year as the first rapid-acting therapy for treatment-resistant depression.Source: Psychiatric Times
Wilkinson Honored with New Investigator Award from ISCTM
Samuel Wilkinson, MD, Assistant Professor of Psychiatry and Assistant Director of the Yale Depression Research Program, has been awarded a New Investigator Award from the International Society of CNS Clinical Trials and Methodology (ISCTM).
New depression drug related to ketamine recommended by FDA panel
Gerard Sanacora, MD, PhD, George D. and Esther S. Gross Professor of Psychiatry; Director of the Yale Depression Research Program; and Co-Director of the Yale New Haven Hospital Interventional Psychiatry Service is featured in a NBC Nightly News report about the drug esketamine.Source: NBC Nighly News
Acute and longer-term outcomes using ketamine as a clinical treatment at the Yale Psychiatric Hospital
Yale researchers, including first author Samuel Wilkinson, MD, Assistant Professor of Psychiatry, describe in a paper published in Biological Psychiatry their experience providing ketamine as a clinical treatment to participants with severe and treatment-resistant mood disorders.Source: Biological Psychiatry
Sanacora featured in CBS This Morning report on ketamine as a treatment for depression
Gerard Sanacora, MD, PhD, Professor of Psychiatry and Director of the Yale Depression Research Program, was interviewed for a CBS This Morning report on the use of ketamine to treat depression.Source: CBS This Morning
Yale Psychiatry ketamine research highlighted in The Washington Post
Gerard Sanacora, MD, PhD, professor of psychiatry and director of the Yale Depression Research Program, is featured in a Washington Post report on the impact the drug ketamine has on people who suffer from depression.Source: The Washington Post
Depression treatments inspired by ketamine move ahead in tests
Antidepressant drugs that work in hours instead of weeks could be on the market within three years, researchers say. "I think it's highly probable that we'll see some version of one of these treatments being approved in the relatively near future," says Dr. Gerard Sanacora, director of the Yale Depression Research Program.Source: NPR
Suicide prevention and ketamine
Suicide, a significant public health problem, is closely linked with mental health conditions, especially depression. At the Yale Depression Research Clinic, a clinical trial is now underway to determine whether esketamine, a form of the drug ketamine, can help prevent suicide in depressed patients.
New drug shows same antidepressant effect as ketamine, study shows
A drug under development seems to have similar antidepressant effects as previously observed with ketamine, but without the same level of dangerous side effects seen when the anesthetic is abused as a party drug, according to a new Yale-led study. Gerard Sanacora, MD, PhD, professor of psychiatry and director of the Yale Depression Research Program, is first author.
Implicit Bias From Providers Inhibits HCV Treatment
A new study reveals significant insights into the challenges that can occur for hepatitis C virus (HCV) micro-elimination efforts in people with HIV (PWH). Due to the opioid epidemic, the prevalence of co-infection with HIV and HCV has been increasing. If left untreated, HCV infection can lead to liver damage, cancer, and death. Although HIV requires lifelong therapy, HCV can be cured with a few months of oral medications.
Alcohol Research Conference Fosters Collaboration Across Specialties
Now in its second year, the Yale Conference for Alcohol Research and Education (YCARE) was held on September 30, 2023. Offering a comprehensive agenda of talks, panel discussions, and poster presentations, the all-day event brought together Yale's researchers, clinicians, and other stakeholders under the banner of alcohol research. Bubu Banini, MD, PhD, assistant professor of medicine (digestive diseases), Yale School of Medicine (YSM), spearheaded the conference, along with co-directors David Fiellin, MD, professor of medicine (general medicine) and emergency medicine, YSM, and public health, Yale School of Public Health; Graeme Mason, PhD, professor of radiology and biomedical imaging and of psychiatry, YSM; and Sherry McKee, PhD, professor of psychiatry, YSM.
Electronic Nicotine Delivery Systems and E-Liquid Modifications to Vape Cannabis Depicted in Online Videos
Rachel Ouellette, PhD; Sophia Selino, BA; and Grace Kong, PhD, are co-authors of a paper in JAMA Network Open that analyzed YouTube videos for use, modification, and marketing of electronic nicotine delivery systems to vape cannabis.Source: JAMA Network Open
Yale Study Finds Genetic Links Between Some Health Conditions and PTSD
A new study led by Yale Department of Psychiatry researchers and published in JAMA Psychiatry has identified numerous physical health conditions, particularly diseases of the cardiovascular and respiratory systems, that have genetic links to post-traumatic stress disorder (PTSD). Gita Pathak, PhD, and Renato Polimanti, PhD, are first and senior authors, respectively.
Yale Contributions Shape ASN Kidney Week 2023
In the world of nephrology, there's one event that stands out above the rest, drawing thousands of professionals from around the globe—the American Society of Nephrology's Kidney Week. This annual event features a rich array of sessions, speakers, and insights into the ever-evolving field of kidney care. This year, Kidney Week takes place in Philadelphia, Pa., with over 12,000 planned attendees.
Screening for Intimate Partner Violence Experience and Use in the Veterans Health Administration
A first-of-its-kind study by Yale School of Medicine researchers revealed high amounts of intimate partner violence involvement among adult patients seeking mental health services at veterans’ health care facilities in the United States.